Navigation Links
GeneGo Receives SBIR Grant
Date:1/12/2010

ST. JOSEPH, Mich., Jan. 12 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today they have been awarded a $336K Phase I SBIR grant from the NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES for creating a novel type of predictive signatures for drug resistance. Under this project GeneGo will develop "regulation signatures" which should overcome many shortcomings of existing methods of molecular diagnostics. For this work GeneGo will utilize its extensive, manually-curated database of signaling interactions and recently developed algorithms for identifying key proteins in signaling networks. The work will be performed in collaboration with the Van Andel Institute for Translational Medicine.  

"What we propose here is the novel concept of using inferred activity of key signaling proteins for building predictive models. Our early results indicate that such models should be significantly more robust than currently available diagnostic applications which are based directly on gene or protein levels. We are very excited about the opportunity provided by NIH support to further develop and validate this approach. If successful, the methodology could be replicated for developing predictive models for sensitivity to a broad range of targeted therapies, leading to a number of diagnostic applications such as specialized molecular tests, systems for formulating combination therapies and procedures for selecting patient cohorts for clinical trials," said Andrej Bugrim, GeneGo COO and PI on the grant.

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscoveryplatform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 6.0, assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 6.0 is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.

SOURCE GeneGo, Inc.

RELATED LINKS
http://www.genego.com

'/>"/>

SOURCE GeneGo, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
2. WorldHeart Receives Unconditional BTT Study Approval From FDA for Levacor(TM) VAD
3. VIA Pharmaceuticals Receives Delisting Notification From NASDAQ
4. KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
5. AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Gram-Negative Bloodstream Pathogens
6. Mylan Receives Tentative FDA Approval Under PEPFAR for Matrix Laboratories New Drug Application (NDA) for Efavirenz Tablets
7. The Make-A-Wish Foundation(R) Receives $1 Million Donation from LATISSE(R) Wishes Campaign
8. BASFs Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label
9. CareCentrix Receives URAC Health Utilization Management Accreditation
10. Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent
11. SRI International Receives U.S. Patent for Needle-Free Transmucosal Drug Delivery System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... --  Divoti USA will engrave and process all ... the latest FDA requirements, which stipulates new criteria regarding medical device ... of Medical ID jewelry such as Medical ID Bracelets, can rest ... terms of the new FDA requirements . ... Divoti offers this dark mark fiber laser engraving ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out many kids ... sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting kids excited ... all ages; it is a non-competitive, non-timed event, which is all about having fun ...
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
Breaking Medicine News(10 mins):